Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.
about
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.
P2860
Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Characterization of a quantita ...... n/kexin type 9 in human serum.
@ast
Characterization of a quantita ...... n/kexin type 9 in human serum.
@en
Characterization of a quantita ...... n/kexin type 9 in human serum.
@nl
type
label
Characterization of a quantita ...... n/kexin type 9 in human serum.
@ast
Characterization of a quantita ...... n/kexin type 9 in human serum.
@en
Characterization of a quantita ...... n/kexin type 9 in human serum.
@nl
prefLabel
Characterization of a quantita ...... n/kexin type 9 in human serum.
@ast
Characterization of a quantita ...... n/kexin type 9 in human serum.
@en
Characterization of a quantita ...... n/kexin type 9 in human serum.
@nl
P2093
P2860
P356
P1476
Characterization of a quantita ...... n/kexin type 9 in human serum.
@en
P2093
Alexander Colbert
Amber Umble-Romero
John Gibbs
Samantha Prokop
Susan Pederson
P2860
P304
P356
10.4161/MABS.28719
P577
2014-04-16T00:00:00Z